Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com
Stephen Wald, MS

Stephen Wald, MS

VP of Chemistry & Pharmaceutical Sciences

Steve is responsible for chemical, analytical and formulation development, and manufacturing scale-up, of Rgenix’s drug candidates. Prior to joining Rgenix, he was Vice President of Manufacturing at Epizyme with similar responsibilities for their Phase 2 oncology assets.

Previously, Steve worked as a consultant for other biotechnology companies, and before that, spent 25 years at Sepracor.  He led Sepracor’s chemistry and pharmaceutical science group that culminated in five NDAs, including oral solids, sterile solutions, and a complex metered dose inhaler.  He also led a new department responsible for the launch and commercial supply of Lunesta® and various respiratory products. He has a M.Sc. in Chemical Engineering degree from the University of California, Berkeley and a B.S. from Cornell University.